REG - N4 Pharma PLC - Posting of Annual Report and Notice of AGM

N4 PharmaAnnouncement

04/03/2020 07:00

RNS Number : 9089E
  
N4 Pharma PLC
  
04 March 2020
  
 

04 March 2020
 
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
 
Posting of Annual Report and Accounts and Notice of AGM
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2019 and Notice of the Annual General Meeting will be posted to shareholders later today, and are available on the Company's website at www.n4pharma.com.
 
The Company's Annual General Meeting will be held at 1:30 p.m. on 31 March 2020 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR. 
 
Enquiries:
 



N4 Pharma Plc
Nigel Theobald, CEO
 


 
Via Scott PR




Allenby Capital Limited
James Reeve/Asha Chotai
 


Tel: +44(0)203 328 5656




Scott PR
Georgia Smith
 


Tel: +44(0)1477 539 539



 
About N4 Pharma
 
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
 
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
NOADXLFBBXLFBBK